Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1975 2
1982 1
1984 1
1985 2
1986 6
1987 6
1988 5
1989 13
1990 7
1992 17
1993 9
1994 19
1995 12
1996 16
1997 19
1998 28
1999 33
2000 30
2001 23
2002 22
2003 32
2004 25
2005 39
2006 50
2007 50
2008 37
2009 31
2010 47
2011 51
2012 43
2013 46
2014 39
2015 49
2016 47
2017 51
2018 40
2019 41
2020 28
2021 41
2022 41
2023 34
2024 39
2025 21
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,087 results

Results by year

Filters applied: . Clear all
Page 1
Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study.
Tokunaga T, Sakashita M, Haruna T, Asaka D, Takeno S, Ikeda H, Nakayama T, Seki N, Ito S, Murata J, Sakuma Y, Yoshida N, Terada T, Morikura I, Sakaida H, Kondo K, Teraguchi K, Okano M, Otori N, Yoshikawa M, Hirakawa K, Haruna S, Himi T, Ikeda K, Ishitoya J, Iino Y, Kawata R, Kawauchi H, Kobayashi M, Yamasoba T, Miwa T, Urashima M, Tamari M, Noguchi E, Ninomiya T, Imoto Y, Morikawa T, Tomita K, Takabayashi T, Fujieda S. Tokunaga T, et al. Among authors: seki n. Allergy. 2015 Aug;70(8):995-1003. doi: 10.1111/all.12644. Epub 2015 May 26. Allergy. 2015. PMID: 25945591 Free PMC article.
[Eosinophilic chronic rhinosinusitis].
Fujieda S, Sakashita M, Tokunaga T, Okano M, Haruna T, Yoshikawa M, Ohtori N, Asaka D, Haruna S, Nakayama T, Ishitoya J, Sakuma Y, Hirakawa K, Takeno S, Himi T, Seki N, Iino Y, Yoshida N, Kobayashi M, Sakaida H, Kondo K, Yamasoba T, Miwa T, Yamada K, Kawata R, Terada T, Kawauchi H, Morikura I, Ikeda K, Murata J, Ikeda H, Noguchi E, Tamari M, Hirota T, Imoto Y, Takabayashi T, Tomita K, Ninomiya T, Morikawa T, Urashima M. Fujieda S, et al. Among authors: seki n. Arerugi. 2015 Feb;64(1):38-45. Arerugi. 2015. PMID: 25779061 Review. Japanese. No abstract available.
[microRNA].
Kojima S, Seki N. Kojima S, et al. Among authors: seki n. Nihon Rinsho. 2016 May 20;74 Suppl 3:201-4. Nihon Rinsho. 2016. PMID: 27344729 Japanese. No abstract available.
Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study.
Fujitani M, Lu X, Shinnakasu R, Inoue T, Kidani Y, Seki NM, Ishida S, Mitsuki S, Ishihara T, Aoki M, Suzuki A, Takahashi K, Takayama M, Ota T, Iwata S, Shibata RY, Sonoyama T, Ariyasu M, Kitano A, Terooatea T, Kelly Villa J, Yamashita K, Yamasaki S, Kurosaki T, Omoto S. Fujitani M, et al. Among authors: seki nm. Front Immunol. 2025 Mar 5;16:1550279. doi: 10.3389/fimmu.2025.1550279. eCollection 2025. Front Immunol. 2025. PMID: 40109335 Free PMC article. Clinical Trial.
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study.
Murata Y, Tanzawa S, Misumi T, Yoshioka H, Miyauchi E, Ninomiya K, Takeshita M, Ito K, Okamoto T, Sugawara S, Kawashima Y, Hashimoto K, Mori M, Miyanaga A, Hayashi A, Tanaka H, Honda R, Nojiri M, Sato Y, Hata A, Masuda K, Kozuki T, Kawamura T, Suzuki T, Yamaguchi T, Asada K, Tetsumoto S, Tanaka H, Watanabe S, Umeda Y, Yamaguchi K, Kuyama S, Tsuruno K, Misumi Y, Kuraishi H, Yoshihara K, Nakao A, Kubo A, Yokoyama T, Watanabe K, Seki N. Murata Y, et al. Among authors: seki n. JTO Clin Res Rep. 2023 Oct 20;4(12):100593. doi: 10.1016/j.jtocrr.2023.100593. eCollection 2023 Dec. JTO Clin Res Rep. 2023. PMID: 38046378 Free PMC article.
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED).
Ishihara M, Kawamura T, Namba Y, Takeyasu Y, Hasegawa Y, Sato Y, Negi Y, Oba T, Sumi T, Hirata H, Funabashi H, Oya Y, Kikuchi H, Katsurada N, Nakatani T, Tanimura K, Nakagawa T, Takeda N, Asami T, Honjo O, Nagashima H, Yamaura T, Hata N, Kitazono M, Nishioka N, Tamiya A, Sakamori Y, Shigaki R, Kaira K, Honda R, Matsui T, Suzuki E, Ito K, Otsuka K, Takase N, Murakami Y, Matsuno K, Inoue S, Kisohara A, Kusumoto S, Aoshima H, Kakizaki Y, Kubo A, Hata A, Ishikawa N, Hamai K, Kanaji N, Misumi T, Matsutani N, Seki N. Ishihara M, et al. Among authors: seki n. Ther Adv Med Oncol. 2025 Jun 16;17:17588359251344010. doi: 10.1177/17588359251344010. eCollection 2025. Ther Adv Med Oncol. 2025. PMID: 40535732 Free PMC article.
1,087 results